Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH001 Combination Therapy in Adjuvant Treatment of Resected Pancreatic Cancer
NCT06353646Recruiting
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label trial of PGV002 in pancreatic cancer (PC) (2 arms). Primary endpoints: Disease-Free Survival at 36 months, Disease-Free Survival Rate at 36 months and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
PGV002
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06353646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353646.